Corebridge Financial Inc. Has $1.79 Million Stake in ICU Medical, Inc. (NASDAQ:ICUI)

Corebridge Financial Inc. reduced its holdings in ICU Medical, Inc. (NASDAQ:ICUI) by 7.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,522 shares of the medical instruments supplier’s stock after selling 902 shares during the quarter. Corebridge Financial Inc.’s holdings in ICU Medical were worth $1,788,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of ICUI. FMR LLC boosted its stake in ICU Medical by 2,676.6% in the third quarter. FMR LLC now owns 104,094 shares of the medical instruments supplier’s stock worth $18,968,000 after purchasing an additional 100,345 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in shares of ICU Medical by 16.5% in the third quarter. BNP Paribas Financial Markets now owns 6,997 shares of the medical instruments supplier’s stock valued at $1,275,000 after buying an additional 991 shares during the last quarter. MetLife Investment Management LLC lifted its position in ICU Medical by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 12,389 shares of the medical instruments supplier’s stock worth $2,258,000 after buying an additional 6,981 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in ICU Medical by 4.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 42,742 shares of the medical instruments supplier’s stock worth $7,788,000 after acquiring an additional 1,751 shares during the last quarter. Finally, Martingale Asset Management L P acquired a new stake in ICU Medical in the 3rd quarter valued at about $255,000. 96.10% of the stock is currently owned by institutional investors.

ICU Medical Stock Performance

ICUI stock opened at $140.38 on Thursday. The company has a quick ratio of 1.03, a current ratio of 2.29 and a debt-to-equity ratio of 0.75. ICU Medical, Inc. has a twelve month low of $93.36 and a twelve month high of $196.26. The business’s fifty day moving average is $152.81 and its 200-day moving average is $163.08. The company has a market cap of $3.44 billion, a P/E ratio of -30.72 and a beta of 0.73.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Raymond James set a $97.00 price target on shares of ICU Medical in a research note on Wednesday, March 12th. StockNews.com lowered ICU Medical from a “buy” rating to a “hold” rating in a research report on Thursday, March 27th. Finally, Jefferies Financial Group upgraded ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 target price for the company in a research report on Wednesday, December 11th. Two equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $168.67.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.